Advanced search
Publication Cover
Journal of Medical Economics Volume 19, 2016 - Issue 6
Submit an article Journal homepage
3,612
Views
44
CrossRef citations to date
0
Altmetric
Respiratory

Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes

Ron GoereeGoeree Consulting Limited, Hamilton, Ontario, Canada; ;McMaster University, Hamilton, Ontario, Canada; Correspondence[email protected]
,
Julie VilleneuveBristol-Myers Squibb Canada, Saint-Laurent, Quebec, Canada;
,
Jeff GoereeGoeree Consulting Limited, Hamilton, Ontario, Canada;
,
John R. PenrodBristol-Myers Squibb, Princeton, New Jersey, USA;
,
Lucinda OrsiniBristol-Myers Squibb, Princeton, New Jersey, USA;
&
Amir Abbas Tahami MonfaredBristol-Myers Squibb Canada, Saint-Laurent, Quebec, Canada; ;Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada
Pages 630-644 | Received 24 Dec 2015, Accepted 03 Feb 2016, Published online: 01 Mar 2016

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related Research Data

Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States
Source: Springer Science and Business Media LLC
Review of economic analyses of treatment for non-small–cell lung cancer (NSCLC)
Source: Informa UK Limited
Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong
Source: Springer Science and Business Media LLC
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
Source: Springer Science and Business Media LLC
A Systematic Review of Economic Evaluations Assessing the Cost-Effectiveness of Licensed Drugs Used for Previously Treated Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Negative Advanced/Metastatic Non-Small Cell Lung Cancer.
Source: Springer Science and Business Media LLC
Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US
Source: Taylor & Francis
Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes
Source: Figshare
Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US
Source: Taylor & Francis

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.